{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:25:45Z","timestamp":1791923145606,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.euo.2022.07.004","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T08:03:43Z","timestamp":1659600223000},"page":"617-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression"],"prefix":"10.1016","volume":"5","author":[{"given":"Michael","family":"Baboudjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Gondran-Tellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Territo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Bastide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Tosoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2022.07.004_b0005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2022.07.004_b0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MOU.0000000000000157","article-title":"Observational studies and the natural history of screen-detected prostate cancer","volume":"25","author":"Albertsen","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0015","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2022.07.004_b0020","unstructured":"EAU. EAU guidelines. Presented at the EAU Annual Congress Amsterdam, 2022. ISBN 978-94-92671-16-5."},{"key":"10.1016\/j.euo.2022.07.004_b0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","article-title":"Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy","volume":"81","author":"Willemse","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","article-title":"Adverse disease features in Gleason score 3\u00a0+\u00a04 \u201cfavorable intermediate-risk\u201d prostate cancer: implications for active surveillance","volume":"72","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0040","doi-asserted-by":"crossref","first-page":"729.e1","DOI":"10.1016\/j.urolonc.2021.02.018","article-title":"Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients","volume":"39","author":"Bloom","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2022.07.004_b0045","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1016\/j.clgc.2020.05.008","article-title":"Active surveillance for intermediate-risk prostate cancer: systematic review and meta-analysis of current protocols and outcomes","volume":"18","author":"Enikeev","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2022.07.004_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00345-021-03893-1","article-title":"Active surveillance for intermediate-risk prostate cancer","volume":"40","author":"Nayan","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bju.14935","article-title":"Active surveillance in intermediate-risk prostate cancer","volume":"125","author":"Klotz","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.07.004_b0060","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2022.07.004_b0065","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2022.07.004_b0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0075","doi-asserted-by":"crossref","first-page":"2917065","DOI":"10.1155\/2016\/2917065","article-title":"Active holistic surveillance: the nutritional aspect of delayed intervention in prostate cancer","volume":"2016","author":"Berg","year":"2016","journal-title":"J Nutr Metab"},{"key":"10.1016\/j.euo.2022.07.004_b0080","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2012.11434.x","article-title":"Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer","volume":"110","author":"Bul","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.07.004_b0085","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1002\/cncr.32202","article-title":"Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer","volume":"125","author":"Butler","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2022.07.004_b0090","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JU.0000000000000742","article-title":"Risk of metastasis in men with grade group 2 prostate cancer managed with active surveillance at a tertiary cancer center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0095","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/JU.0000000000001937","article-title":"Factors associated with time to conversion from active surveillance to treatment for prostate cancer in a multi-institutional cohort","volume":"206","author":"Cooley","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","article-title":"Outcomes of active surveillance for men with intermediate-risk prostate cancer","volume":"29","author":"Cooperberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2022.07.004_b0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.6004\/jnccn.2021.7065","article-title":"Metastasis and mortality in men with low- and intermediate-risk prostate cancer on active surveillance","volume":"20","author":"Courtney","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2022.07.004_b0110","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the G\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bju.13715","article-title":"Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?","volume":"120","author":"Herden","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.07.004_b0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2022.07.004_b0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2014.06.010","article-title":"Five-year nationwide follow-up study of active surveillance for prostate cancer","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.euo.2018.04.018","article-title":"Effects of initial Gleason grade on outcomes during active surveillance for prostate cancer","volume":"1","author":"Masic","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2022.07.004_b0135","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.juro.2016.12.047","article-title":"Active surveillance for favorable risk prostate cancer in African Caribbean men: results of a prospective study","volume":"197","author":"Meunier","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2020.12.005","article-title":"Active surveillance\u2014is it feasible for intermediate-risk localised prostate cancer?","volume":"24","author":"Mukherjee","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2022.07.004_b0145","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.juro.2017.03.123","article-title":"Intermediate-term outcomes for men with very low\/low and intermediate\/high risk prostate cancer managed by active surveillance","volume":"198","author":"Nyame","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4111\/icu.20200601","article-title":"Active surveillance in males with low- to intermediate-risk localized prostate cancer: a modern prospective cohort study","volume":"62","author":"Rakauskas","year":"2021","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5489\/cuaj.6328","article-title":"The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: results from a large, population-based cohort","volume":"14","author":"Richard","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2022.07.004_b0165","doi-asserted-by":"crossref","first-page":"605.e1","DOI":"10.1016\/j.urolonc.2017.06.048","article-title":"Identifying intermediate-risk candidates for active surveillance of prostate cancer","volume":"35","author":"Savdie","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2022.07.004_b0170","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.5489\/cuaj.7272","article-title":"Active surveillance in favorable intermediate-risk prostate cancer patients: predictors of deferred intervention and treatment choice","volume":"16","author":"Sayyid","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2022.07.004_b0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.urology.2019.04.017","article-title":"Three-year active surveillance outcomes in a contemporary community urology cohort in the United States","volume":"130","author":"Shelton","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euo.2022.07.004_b0180","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jnci\/djq154","article-title":"Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study","volume":"102","author":"Stattin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2022.07.004_b0185","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2018.09.045","article-title":"Active surveillance for localized prostate cancer: nationwide observational study","volume":"201","author":"Thomsen","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/21681805.2017.1380697","article-title":"Active surveillance for localized prostate cancer: update of a prospective single-center cohort","volume":"52","author":"Thostrup","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0195","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/j.clgc.2017.10.007","article-title":"Oncologic outcomes of definitive treatments for low- and intermediate-risk prostate cancer after a period of active surveillance","volume":"16","author":"Whalen","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2022.07.004_b0200","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.juro.2015.11.075","article-title":"Metastatic prostate cancer in men initially treated with active surveillance","volume":"195","author":"Yamamoto","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0205","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2022.07.004_b0210","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","article-title":"Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received","volume":"77","author":"Neal","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0215","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0220","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s00345-021-03703-8","article-title":"Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review","volume":"39","author":"Laukhtina","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0225","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2016.01.120","article-title":"Prognostic value of percent Gleason grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence","volume":"196","author":"Cole","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0230","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.eururo.2014.10.010","article-title":"Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0235","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.07.004_b0240","doi-asserted-by":"crossref","unstructured":"Shore ND, Renzulli J, Fleshner NE, et al. Active surveillance plus enzalutamide monotherapy vs active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial. JAMA Oncol. In press. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1641.","DOI":"10.1001\/jamaoncol.2022.1641"},{"key":"10.1016\/j.euo.2022.07.004_b0245","article-title":"Impact of pathology review for decision therapy in localized prostate cancer","volume":"10","author":"Us\u00f3n Junior","year":"2017","journal-title":"Clin Med Insights Pathol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931122001353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931122001353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:18Z","timestamp":1762876098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931122001353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2588931122001353"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2022.07.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2022.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}